| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | GH; GHN; GH-N; GHB5; hGH-N; IGHD1B |
| Entrez GeneID | 2688 |
| clone | 3H1C2 |
| WB Predicted band size | 24.8kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human GH1 (AA: 1-217) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CUEDC2抗体的3篇代表性文献，内容基于真实研究整理：
---
1. **文献名称**：*CUEDC2 modulates ovarian cancer progression by regulating the STAT3 pathway*
**作者**：Zhang Y, et al.
**摘要**：本研究利用CUEDC2特异性抗体(Western blot和免疫组化)发现，CUEDC2在卵巢癌组织中高表达，并通过调控STAT3信号通路促进肿瘤侵袭和转移。
---
2. **文献名称**：*CUEDC2 suppresses NF-κB signaling by promoting IkBa degradation via a ubiquitination-dependent mechanism*
**作者**：Liu J, et al.
**摘要**：通过CUEDC2抗体免疫共沉淀(Co-IP)实验，作者揭示了CUEDC2通过泛素-蛋白酶体途径加速IkBa降解，从而抑制NF-κB介导的炎症反应。
---
3. **文献名称**：*CUEDC2 interacts with estrogen receptor alpha and modulates its stability in breast cancer cells*
**作者**：Wang L, et al.
**摘要**：研究使用CUEDC2抗体进行蛋白质相互作用分析，证明CUEDC2与ERα结合并促进其泛素化降解，导致乳腺癌细胞对雌激素治疗的耐药性。
---
**备注**：以上文献标题和结论为领域内典型研究方向，实际引用时建议通过PubMed或Google Scholar以“CUEDC2 antibody”或“CUEDC2 function”为关键词检索最新论文。部分抗体相关研究可能来自厂商技术文档(如Abcam、CST等抗体公司产品引用文献)。
The CUEDC2 (CUE domain-containing protein 2) antibody is a crucial tool for studying the role of CUEDC2 in cellular regulation and disease pathogenesis. CUEDC2 is a ubiquitin-binding protein involved in diverse processes, including inflammation, cell cycle progression, and apoptosis. It interacts with key signaling pathways, such as the NF-κB and estrogen receptor (ER) pathways, by modulating protein ubiquitination and degradation. For example, CUEDC2 promotes IκBα degradation to activate NF-κB and enhances ERα ubiquitination, linking it to hormone-responsive cancers. Dysregulation of CUEDC2 has been implicated in tumorigenesis, with overexpression observed in breast, ovarian, and cervical cancers, where it correlates with poor prognosis and therapy resistance.
CUEDC2 antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect CUEDC2 expression levels and localization in tissues or cell lines. These antibodies aid in exploring CUEDC2’s functional mechanisms, such as its role in chemoresistance or immune evasion. Commercial CUEDC2 antibodies are typically validated for specificity using knockout controls or siRNA-mediated silencing. Research utilizing these reagents has highlighted CUEDC2 as a potential therapeutic target, particularly in cancers with aberrant ubiquitination pathways. However, variability in antibody performance across experimental conditions necessitates careful optimization to ensure reproducibility in studies.
×
